Key Takeaways:
AbbVie Inc. (NYSE: ABBV) unit Allergan Aesthetics received a positive opinion from a key European regulatory panel for its new frown-line treatment, Boey®, recommending its approval across 30 European markets.
"A positive opinion for Boey® reflects years of scientific innovation and clinical development aimed at advancing botulinum toxin science," Roopal Thakkar, chief scientific officer at AbbVie, said in a statement.
The recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) was supported by data from two Phase 3 trials. The studies showed the treatment, trenibotulinumtoxinE, had a rapid onset as early as eight hours and an efficacy duration of two to three weeks, with a safety profile similar to placebo.
A final decision from the European Commission is expected in the coming months. Approval would de-risk the European launch for AbbVie, opening a new revenue stream for its aesthetics portfolio and positioning Boey® as a differentiated treatment in the competitive facial injectables market.
The CHMP's backing is for the temporary improvement of moderate to severe glabellar lines, the vertical lines that appear between the eyebrows. If formally approved, Boey® would be the first and only botulinum neurotoxin serotype E available to patients for this use, offering a new option for a market that includes well-established products like Botox, also from Allergan.
The two pivotal studies, M21-500 and M21-508, met all primary and secondary endpoints, demonstrating both efficacy and safety across up to three consecutive treatments. Allergan Aesthetics said it is preparing for a commercial launch in the upcoming months and that marketing submissions are also under review in several other countries.
The positive regulatory step provides a boost for AbbVie's aesthetics franchise. Shares of AbbVie were recently trading down 0.68 percent at $212.41 on volume lighter than its 20-day average.
This development signals a potential expansion of AbbVie’s market share in the aesthetics space, where it competes with companies like Johnson & Johnson (JNJ) and Eli Lilly (LLY). Investors will now watch for the final European Commission decision later this year, which will be the next major event for the product's launch.
This article is for informational purposes only and does not constitute investment advice.
